Search Results

Five-Year ARTS II Outcomes Reported for SES

March 16, 2010—Patrick W. Serruys, MD, PhD, et al published findings from a study that sought to compare the 5-year clinical outcomes, safety, and efficacy of sirolimus-eluting stents (SES) in ARTS II (Arterial Revascularization Therapies Study II) with the outcomes of coronary artery bypass grafting (CABG) and bare-metal stents (BMS) from the ARTS I study. The background of the study is that the long-term outcome after SES implantation in patients with multivessel disease had yet to be established. The findings were published in the Journal of the American College of Cardiology (2010;55:1093–1101).

Three-Year SYNTAX Data Support Global Risk to Evaluate PCI

June 20, 2012—Patrick W. Serruys, MD, et al published 3-year data from the SYNTAX trial in the Journal of the American College of Cardiology: Cardiovascular Interventions (2012;5:606–617). The aim of this study was to assess the additional value of Global Risk—a combination of the SYNTAX score and EuroSCORE—in the identification of a low-risk population who could safely and efficaciously be treated with coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI).

Editorial Addresses European Industry Proposal to Withdraw Direct Sponsorships of Conference Attendees

November 23, 2015—Patrick W. Serruys, MD, Editor-in-Chief of EuroIntervention; William Wijns, MD, Chairman of PCR; and Stephan Windecker, President of EAPCI, the European Association of Percutaneous Cardiovascular Interventions, announced the expedited publication of their editorial in EuroIntervention, which addresses an upcoming Eucomed vote that will influence sponsorship of continuing medical education (CME). 

Dynamics of Vessel Wall Changes Studied After Absorb Bioresorbable Scaffold Implantation

December 2, 2013—In EuroIntervention, Patrick W. Serruys, MD, et al published findings online ahead of print from a study conducted to assess observations with multimodality imaging of the Absorb bioresorbable everolimus-eluting vascular scaffold (Abbott Vascular, Santa Clara, CA) performed in two consecutive cohorts of patients who were serially investigated either at 6 and 24 months or at 12 and 36 months. The investigators looked at patients from the ABSORB clinical investigation, cohort B (ABSORB B).

2-Year Results of Abbott's ABSORB Trial Published

Study of EXCEL Data Finds That Sex Is Not an Independent Predictor of Adverse Revascularization Outcomes

July 10, 2018—Patrick W. Serruys, MD, et al published findings from a study to assess outcomes after percutaneous coronary intervention (PCI) and coronary artery bypass grafting surgery (CABG) according to sex in the large randomized EXCEL trial of patients with unprotected left main disease. The study was published online in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

Abbott Vascular's Absorb BVS Demonstrates Noninferiority to Xience DES in STEMI Patients

September 1, 2015—The European Society of Cardiology announced that Prof.

Five-Year LEADERS Data Compare Biolimus-Eluting Stents Versus Sirolimus-Eluting Stents

August 19, 2013—The final 5-year report of the LEADERS trial was published by Patrick W. Serruys, MD, et al in the Journal of American College of Cardiology (JACC): Cardiovascular Interventions (2013;6:777–789). The investigators noted that the landmark LEADERS (Limus Eluted From a Durable Versus Erodable Stent Coating) trial is the first randomized study to evaluate biodegradable polymer-based drug-eluting stents (DES) against durable polymer DES.

Biosensors Announces Large Global Trial of BioMatrix Flex DES

May 18, 2011—Biosensors International Group, Ltd. (Singapore) announced plans for the Global LEADERS (LEADERS II) randomized clinical trial, which involves a head-to-head comparison between two drug-eluting stents (DES).

One-Year ABSORB II Data Support Abbott's Absorb Bioresorbable Vascular Scaffold

September 14, 2014—Abbott Vascular announced 1-year clinical results from the ABSORB II prospective randomized controlled trial comparing the safety and effectiveness of Abbott’s Absorb coronary bioresorbable vascular scaffold (BVS) to the company’s Xience family of drug-eluting stents.

German TRAMI Registry Continues to Support MitraClip Use In Elderly Patients

April 12, 2013—Results from the German TRAMI (Transcatheter Mitral Valve) registry are available online ahead of print in EuroIntervention.

Multivessel TALENT Trial of SMT’s Supraflex Cruz Stent Completes Enrollment

October 3, 2024—Sahajanand Medical Technologies Pvt Ltd (SMT) announced the completion of patient enrollment in the Multivessel TALENT trial, which aims to further validate the capabilities of the company’s Supraflex Cruz stents in addressing some of the most challenging coronary conditions.

Abbott Vascular's Absorb Vascular Scaffold Approved in Europe

January 10, 2011—Abbott Vascular (Santa Clara, CA) announced that it has received CE Mark approval for the drug-eluting Absorb bioresorbable vascular scaffold for treating coronary artery disease.

SYNTAX III Revolution Trial Evaluates CT as a Decision-Making Tool for Complex Coronary Disease

October 15, 2018—GE Healthcare announced the publication of a study that used the company's imaging system, the Healthcare Revolution CT, to demonstrate that CT can be a useful aid in heart team decision-making for complex coronary disease.

Abbott's 6-Month ABSORB Data Presented at PCR

May 25, 2010—Abbott Vascular (Santa Clara, CA) announced 6-month results from the first 45 patients enrolled in the second stage of the ABSORB trial of the company's bioresorbable vascular scaffold (BVS).

Abbott's 6-Month ABSORB Data Presented at PCR

May 25, 2010—Abbott Vascular (Santa Clara, CA) announced 6-month results from the first 45 patients enrolled in the second stage of the ABSORB trial of the company's bioresorbable vascular scaffold (BVS).

Data From SYNTAX III Revolution Trial Presented at EuroPCR

May 23, 2018—Results from the SYNTAX III Revolution trial were presented at EuroPCR 2018, held May 21–25 in Paris, France.

Abbott Vascular Presents 3-Year SPIRIT II Data at ACC

March 29, 2009—Abbott Vascular (Santa Clara, CA) announced that long-term data presented from the company's SPIRIT II clinical trial demonstrated that the clinical advantages of the Xience V everolimus-eluting coronary stent system continued to increase between 2 and 3 years compared to Boston Scientific Corporation's (Natick, MA) Taxus Express² paclitaxel-eluting coronary stent system and the Taxus Liberté paclitaxel-eluting coronary stent system.